A phase 2, open-label study of MAC-321 [milataxel] administered intravenously as a single agent for the treatment of non-small cell lung cancer refractory to platinum-based therapy.

Trial Profile

A phase 2, open-label study of MAC-321 [milataxel] administered intravenously as a single agent for the treatment of non-small cell lung cancer refractory to platinum-based therapy.

Completed
Phase of Trial: Phase II

Latest Information Update: 25 Aug 2009

At a glance

  • Drugs Milataxel (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Wyeth
  • Most Recent Events

    • 25 Aug 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 25 Aug 2009 Actual number of patients (48) and actual end date (Feb 2005) added as reported by ClinicalTrials.gov.
    • 17 Oct 2006 Status change
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top